This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jeng, M.-H. Articles by Jordan, V. C. Search for Related Content PubMed PubMed Citation Articles by Jeng, M.-H. Articles by Jordan, V. C.

Estrogenic Potential of Progestins in Oral Contraceptives to Stimulate Human Breast Cancer Cell Proliferation¹

Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792

² To whom requests for reprints should be addressed, at Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792.

Most oral contraceptives (OC) contain a progestin in combination with an estrogen, and the progestin component in OC includes one of the following 19-nortestosterone derivatives: norethynodrel; norethindrone; or norgestrel (levonorgestrel). It is well known that estrogens promote the growth of breast cancer. However, progestins have recently also been implicated in the development of breast cancer. We have compared and contrasted the ability of synthetic progestins to stimulate the proliferation of cultured human breast cancer cells and examined their possible mechanism of action.

We found that some progestins used in OC were able to stimulate the growth of estrogen receptor-positive (ER⁺) MCF-7 and T47DA18 human breast cancer cells but not ER^– MDA-MB-231, BT-20, and T47DC4 human breast cancer cells. However, two other progestins, MPA and R5020, which are not used in OC, were either not able to stimulate or only slightly stimulated growth. The potency of norethynodrel [median effective dose (EC₅₀) = 4 x 10^–8 M] and norethindrone (EC₅₀ = 3 x 10^–8 M) was greater than norgestrel (EC₅₀ = 2 x 10^–7 M) in MCF-7 cells. E₂ (EC₅₀ = 8 x 10^–13 M) was an even more potent stimulator of growth. More importantly, the progestin-induced growth stimulation was blocked by the antiestrogens 4-hydroxytamoxifen and ICI 164,384 but not the antiprogestin 17β-hydroxy-11β-(4-dimethylaminophenyl)-17-(1-propynyl)-estra-4,9-dien-3-one (RU486). To determine whether the proliferative action of progestins was mediated through the ER, cells were transfected with a chloramphenicol acetyltransferase reporter gene containing an estrogen response element derived from vitellogenin 2A gene. The progestins which stimulated the growth of breast cancer cells also increased chloramphenicol acetyltransferase activity. The induction of chloramphenicol acetyltransferase activity was blocked by the addition of the antiestrogens 4-hydroxytamoxifen and ICI 164,384 but not the antiprogestin RU486.

This study provides direct evidence that the 19-nortestosterone derivatives in OC have estrogenic properties and suggests that activation of ER, but not progesterone receptor, is the growth-stimulatory mechanism for these synthetic progestins. Our results may help to explain the conflicting evidence linking OC and breast cancer risk. A rigorous evaluation of the "total" estrogenic potential of OC might produce a better correlation with breast cancer risk.

¹ Supported by Grant RO1 CA32713.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 5/18/92. Accepted 9/17/92.

This article has been cited by other articles:

				H. B. Nichols, A. Trentham-Dietz, K. M. Egan, L. Titus-Ernstoff, J. M. Hampton, and P. A. Newcomb Oral Contraceptive Use and Risk of Breast Carcinoma In situ Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2262 - 2268. [Abstract] [Full Text] [PDF]

				P. A. Wingo, H. Austin, P. A. Marchbanks, M. K. Whiteman, J. Hsia, M. G. Mandel, H. B. Peterson, and H. W. Ory Oral Contraceptives and the Risk of Death From Breast Cancer Obstet. Gynecol., October 1, 2007; 110(4): 793 - 800. [Abstract] [Full Text] [PDF]

				I. Benakanakere, C. Besch-Williford, J. Schnell, S. Brandt, M. R. Ellersieck, A. Molinolo, and S. M. Hyder Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats. Clin. Cancer Res., July 1, 2006; 12(13): 4062 - 4071. [Abstract] [Full Text] [PDF]

				Z.-Y. Zheng, B.-H. Bay, S.-E. Aw, and V. C-L. Lin A Novel Antiestrogenic Mechanism in Progesterone Receptor-transfected Breast Cancer Cells J. Biol. Chem., April 29, 2005; 280(17): 17480 - 17487. [Abstract] [Full Text] [PDF]

				A. Skildum, E. Faivre, and C. A. Lange Progesterone Receptors Induce Cell Cycle Progression via Activation of Mitogen-Activated Protein Kinases Mol. Endocrinol., February 1, 2005; 19(2): 327 - 339. [Abstract] [Full Text] [PDF]

				S. N. Lauber, S. Ali, and N. J. Gooderham The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity Carcinogenesis, December 1, 2004; 25(12): 2509 - 2517. [Abstract] [Full Text] [PDF]

				T. Sumida, Y. Itahana, H. Hamakawa, and P.-Y. Desprez Reduction of Human Metastatic Breast Cancer Cell Aggressiveness on Introduction of Either Form A or B of the Progesterone Receptor and Then Treatment with Progestins Cancer Res., November 1, 2004; 64(21): 7886 - 7892. [Abstract] [Full Text] [PDF]

				V. C. L. Lin, C. T. Woon, S. E. Aw, and C. Guo Distinct Molecular Pathways Mediate Progesterone-Induced Growth Inhibition And Focal Adhesion Endocrinology, December 1, 2003; 144(12): 5650 - 5657. [Abstract] [Full Text] [PDF]

				H. E. Cunliffe, M. Ringner, S. Bilke, R. L. Walker, J. M. Cheung, Y. Chen, and P. S. Meltzer The Gene Expression Response of Breast Cancer to Growth Regulators: Patterns and Correlation with Tumor Expression Profiles Cancer Res., November 1, 2003; 63(21): 7158 - 7166. [Abstract] [Full Text] [PDF]

				J. M Dopp and J. M Kolesar Risk of breast cancer associated with hormone replacement therapy Journal of Oncology Pharmacy Practice, September 1, 1999; 5(3): 109 - 116. [Abstract] [PDF]

				V. C-L. Lin, E. H. Ng, S. E. Aw, M. G-K. Tan, E. H-L. Ng, V. S-W. Chan, and G. H. Ho Progestins Inhibit the Growth of MDA-MB-231 Cells Transfected with Progesterone Receptor Complementary DNA Clin. Cancer Res., February 1, 1999; 5(2): 395 - 403. [Abstract] [Full Text] [PDF]

				M.-H. Jeng, M. A. Shupnik, T. P. Bender, E. H. Westin, D. Bandyopadhyay, R. Kumar, S. Masamura, and R. J. Santen Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells Endocrinology, October 1, 1998; 139(10): 4164 - 4174. [Abstract] [Full Text] [PDF]

				M.-H. Jeng, C. Kao, L. Sivaraman, S. Krnacik, L. W. K. Chung, D. Medina, O. M. Conneely, and B. W. O'Malley Reconstitution of Estrogen-Dependent Transcriptional Activation of an Adenoviral Target Gene in Select Regions of the Rat Mammary Gland Endocrinology, June 1, 1998; 139(6): 2916 - 2925. [Abstract] [Full Text] [PDF]